Cargando…

The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice

Bone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its op...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Tingting, Xie, Yuan, Huang, Jing, Li, Ping, Wang, Xuliang, Yan, Yaoyao, Xia, Tianhe, Li, Lei, Zhu, Feng, Li, Hao, Wu, Rongzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736900/
https://www.ncbi.nlm.nih.gov/pubmed/29362568
http://dx.doi.org/10.1155/2017/3258035
_version_ 1783287440713187328
author Wu, Tingting
Xie, Yuan
Huang, Jing
Li, Ping
Wang, Xuliang
Yan, Yaoyao
Xia, Tianhe
Li, Lei
Zhu, Feng
Li, Hao
Wu, Rongzhou
author_facet Wu, Tingting
Xie, Yuan
Huang, Jing
Li, Ping
Wang, Xuliang
Yan, Yaoyao
Xia, Tianhe
Li, Lei
Zhu, Feng
Li, Hao
Wu, Rongzhou
author_sort Wu, Tingting
collection PubMed
description Bone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its optimal intervention timer potential mechanisms. In our study, we concentrated on finding an optimal time window to perform BMSCs treatment in a murine model of myocarditis induced by coxsackievirus B3 (CVB3). On the 1st day, 3rd day, 7th day, and 14th day after BALB/c mice were infected by CVB3, we intravenously injected equivalent BMSCs into the treatment groups. With a 28-day follow-up after inoculation, we found that the ventricular function was significantly improved in the BMSCs treatment group and cardiac fibrosis markedly ameliorated, especially when BMSCs were injected between 1 and 2 weeks after CVB3 inoculation. Furthermore, we demonstrated that after BMSCs treatment, the expressions of TGF-β, col1α1, and col3α1 were significantly decreased. Therefore, we conclude that BMSCs may have a potential to improve CVB3-induced myocarditis by ameliorating cardiac fibrosis through the inhibition of TGF-β expression.
format Online
Article
Text
id pubmed-5736900
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57369002018-01-23 The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice Wu, Tingting Xie, Yuan Huang, Jing Li, Ping Wang, Xuliang Yan, Yaoyao Xia, Tianhe Li, Lei Zhu, Feng Li, Hao Wu, Rongzhou Stem Cells Int Research Article Bone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its optimal intervention timer potential mechanisms. In our study, we concentrated on finding an optimal time window to perform BMSCs treatment in a murine model of myocarditis induced by coxsackievirus B3 (CVB3). On the 1st day, 3rd day, 7th day, and 14th day after BALB/c mice were infected by CVB3, we intravenously injected equivalent BMSCs into the treatment groups. With a 28-day follow-up after inoculation, we found that the ventricular function was significantly improved in the BMSCs treatment group and cardiac fibrosis markedly ameliorated, especially when BMSCs were injected between 1 and 2 weeks after CVB3 inoculation. Furthermore, we demonstrated that after BMSCs treatment, the expressions of TGF-β, col1α1, and col3α1 were significantly decreased. Therefore, we conclude that BMSCs may have a potential to improve CVB3-induced myocarditis by ameliorating cardiac fibrosis through the inhibition of TGF-β expression. Hindawi 2017 2017-12-05 /pmc/articles/PMC5736900/ /pubmed/29362568 http://dx.doi.org/10.1155/2017/3258035 Text en Copyright © 2017 Tingting Wu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wu, Tingting
Xie, Yuan
Huang, Jing
Li, Ping
Wang, Xuliang
Yan, Yaoyao
Xia, Tianhe
Li, Lei
Zhu, Feng
Li, Hao
Wu, Rongzhou
The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice
title The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice
title_full The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice
title_fullStr The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice
title_full_unstemmed The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice
title_short The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice
title_sort optimal intervention time of bone marrow mesenchymal stem cells in ameliorating cardiac fibrosis induced by viral myocarditis: a randomized controlled trial in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736900/
https://www.ncbi.nlm.nih.gov/pubmed/29362568
http://dx.doi.org/10.1155/2017/3258035
work_keys_str_mv AT wutingting theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT xieyuan theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT huangjing theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT liping theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT wangxuliang theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT yanyaoyao theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT xiatianhe theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT lilei theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT zhufeng theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT lihao theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT wurongzhou theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT wutingting optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT xieyuan optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT huangjing optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT liping optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT wangxuliang optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT yanyaoyao optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT xiatianhe optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT lilei optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT zhufeng optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT lihao optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice
AT wurongzhou optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice